Accolade (NASDAQ:ACCD) PT Lowered to $13.00 at Stifel Nicolaus

Accolade (NASDAQ:ACCD) had its price objective reduced by stock analysts at Stifel Nicolaus from $15.00 to $13.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 39.04% from the company’s previous close.

Several other analysts have also commented on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research report on Monday, February 26th. Wells Fargo & Company lifted their price objective on shares of Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 9th. Piper Sandler boosted their price target on shares of Accolade from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Tuesday, January 9th. Needham & Company LLC reissued a “buy” rating and issued a $17.00 price target on shares of Accolade in a research report on Friday, January 19th. Finally, Truist Financial boosted their price target on shares of Accolade from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Accolade has an average rating of “Moderate Buy” and an average target price of $15.53.

Accolade Stock Performance

Shares of ACCD stock opened at $9.35 on Monday. The firm has a market cap of $723.78 million, a price-to-earnings ratio of -5.67 and a beta of 2.08. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. Accolade has a 52 week low of $6.33 and a 52 week high of $17.00. The firm’s 50-day simple moving average is $9.90 and its two-hundred day simple moving average is $9.92.

Institutional Investors Weigh In On Accolade

A number of institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC boosted its stake in shares of Accolade by 12.6% in the 4th quarter. ARK Investment Management LLC now owns 6,805,208 shares of the company’s stock valued at $81,731,000 after purchasing an additional 762,685 shares in the last quarter. Vanguard Group Inc. raised its holdings in Accolade by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,283,858 shares of the company’s stock valued at $55,903,000 after buying an additional 157,464 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in Accolade by 3.3% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,913,000 shares of the company’s stock valued at $30,820,000 after buying an additional 93,000 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Accolade by 2.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,921,676 shares of the company’s stock valued at $23,083,000 after buying an additional 50,311 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Accolade by 111.1% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,798,993 shares of the company’s stock valued at $19,033,000 after buying an additional 946,970 shares during the last quarter. Hedge funds and other institutional investors own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.